Chinook Therapeutics, Inc. (NASDAQ:KDNY) has received an average rating of “Buy” from the nine analysts that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $31.71.
Several equities research analysts have recently commented on KDNY shares. Bloom Burton restated a “buy” rating and set a $40.00 price objective on shares of Chinook Therapeutics in a report on Monday, June 14th. Zacks Investment Research upgraded Chinook Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 4th.
In other news, Director Davis Jerel sold 850,000 shares of the company’s stock in a transaction on Friday, August 27th. The stock was sold at an average price of $14.00, for a total transaction of $11,900,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Eric Dobmeier purchased 7,000 shares of the company’s stock in a transaction dated Wednesday, August 18th. The shares were purchased at an average cost of $11.74 per share, for a total transaction of $82,180.00. The disclosure for this purchase can be found here. 29.75% of the stock is owned by insiders.
Shares of KDNY traded down $0.34 during mid-day trading on Friday, reaching $12.13. 5,640 shares of the company were exchanged, compared to its average volume of 232,475. Chinook Therapeutics has a 52 week low of $10.95 and a 52 week high of $21.68. The stock has a market capitalization of $543.42 million, a PE ratio of -3.02 and a beta of 0.06. The business has a 50 day simple moving average of $13.18 and a two-hundred day simple moving average of $15.18.
Chinook Therapeutics (NASDAQ:KDNY) last issued its quarterly earnings data on Thursday, August 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.76) by $0.08. The company had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.25 million. Chinook Therapeutics had a negative return on equity of 52.69% and a negative net margin of 2,885.36%. Equities research analysts predict that Chinook Therapeutics will post -3.57 EPS for the current fiscal year.
Chinook Therapeutics Company Profile
Chinook Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.
Further Reading: Put Option
Receive News & Ratings for Chinook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chinook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.